The mission of the Cancer Immunology Program is to generate new insights into the mechanisms that regulate the anti-tumor immune response and to translate this information into efficacious immunotherapies for cancer patients. The central hypothesis is that a deeper understanding ofthe requirements for effective innate and adaptive host responses will advance the development of treatment strategies that overcome tumor immune escape. The Program is led by G. Dranoff(DFCI) and K. Wucherpfennig (DCFI), and includes 86 faculty members representing all seven member institutions and 13 departments of HMS and HSPH. The Program has been NCI funded since the consortium received its first CCSG in 2000, and was rated outstanding at the last CCSG renewal in 2005. In the current budget year, Program members generated $37.5 million (total costs) in peer-reviewed grant support, with $8.4 million in funding from the NCI. The total number of publications from members of the Program over the project period was 1,508 (2006 to 2010);14% were intra-programmatic, 24% were inter-programmatic and 18% were inter-institutional. Thematically. the Program is broadly divided into investigative efforts in bone marrow transplantation, adoptive cellular therapies and cancer vaccines. Regular workshops serve to disseminate ongoing research findings, increase knowledge of cancer immunology within the Harvard Immunology community and stimulate collaborations among basic and clinical scientists. An active clinical immunotherapy program across the Dana-Farber/Harvard Cancer Center institutions provides interactions and collaborations between the Program and numerous disease-focused Programs. Multiple DF/HCC Shared Resources advance the Program's research and clinical activities. During the current project period, the Program has had three specific aims. These are: 1. To increase our understanding of the immune mechanisms that contribute to tumor development. 2. To improve the therapeutic activity and minimize the toxicities of bone marrow transplantation and adoptive cellular therapies. 3. To improve the therapeutic activity and minimize the toxicities of cancer vaccines.

Public Health Relevance

The Cancer Immunology Program of DF/HCC aims to generate new information about the immune response to cancer and then to apply this knowledge to advance the development of efficacious and safe immunotherapies. The Program brings together laboratory and clinical scientists to accelerate the translation of basic discoveries in immunology to the improvement of patient outcomes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-48
Application #
8469414
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
48
Fiscal Year
2013
Total Cost
$85,483
Indirect Cost
$63,431
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Hu, Yanhui; Comjean, Aram; Roesel, Charles et al. (2016) FlyRNAi.org-the database of the Drosophila RNAi screening center and transgenic RNAi project: 2017 update. Nucleic Acids Res :
Hong, Theodore S; Wo, Jennifer Y; Yeap, Beow Y et al. (2016) Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol 34:460-8
Freedman, Rachel A; Gelman, Rebecca S; Wefel, Jeffrey S et al. (2016) Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol 34:945-52
Mohr, Stephanie E; Hu, Yanhui; Ewen-Campen, Benjamin et al. (2016) CRISPR guide RNA design for research applications. FEBS J 283:3232-8
Brunner, Andrew M; Li, Shuli; Fathi, Amir T et al. (2016) Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol 175:496-504
Cox, Andrew G; Hwang, Katie L; Brown, Kristin K et al. (2016) Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth. Nat Cell Biol 18:886-96
McKay, Tina B; Hjortdal, Jesper; Sejersen, Henrik et al. (2016) Endocrine and Metabolic Pathways Linked to Keratoconus: Implications for the Role of Hormones in the Stromal Microenvironment. Sci Rep 6:25534
Nelms, Bradlee D; Waldron, Levi; Barrera, Luis A et al. (2016) CellMapper: rapid and accurate inference of gene expression in difficult-to-isolate cell types. Genome Biol 17:201
Tan, Justin L; Fogley, Rachel D; Flynn, Ryan A et al. (2016) Stress from Nucleotide Depletion Activates the Transcriptional Regulator HEXIM1 to Suppress Melanoma. Mol Cell 62:34-46
Johnson, Shawn F; Cruz, Cristina; Greifenberg, Ann Katrin et al. (2016) CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell Rep 17:2367-2381

Showing the most recent 10 out of 303 publications